Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Free Report

White Paper_2017_State of China Life Science

State of China Life Science - 2017H1

Over $10B invested in last 18 months! Download free report on life science investment in China.

MicuRx Pharma Picks Next-Gen MRSA Antibiotic Candidate

publication date: Aug 19, 2008
View a Printer Friendly version of this page, allowing you to print the page.

MicuRx Pharmaceuticals, Inc., a privately held company based in the US and Shanghai, China, named its first preclinical development candidate. MicuRX is developing next-generation antibiotics aimed at multi-drug resistant gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). At the same time, the company moved into a new 10,000 square foot laboratory in ZhangJiang HighTech Park in Shanghai. The company had previously presented at the ChinaBio® Investor Forum held in Shanghai last December. More details...

Stock Symbol: (NYSE: PFE)



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China